A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Ravagalimab

Subcutaneous Injection

Trial Locations (1)

Acpru /Id# 265325, Grayslake